Cargando…
Naoxintong Retards Atherosclerosis by Inhibiting Foam Cell Formation through Activating PPARα Pathway
BACKGROUNDS: We recently reported that Naoxintong (NXT), a China Food and Drug Administration (FDA)-approved cardiac medicine, could reduce the plaque size, but the underlying mechanism remains elusive now. OBJECTIVE: In this study, we investigated the effects of NXT on foam cell accumulation both i...
Autores principales: | Wang, Zeng, Shi, Huairui, Zhao, Huan, Dong, Zhen, Zhao, Buchang, Weng, Xinyu, Liu, Rongle, Hu, Kai, Zou, Yunzeng, Sun, Aijun, Ge, Junbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463403/ https://www.ncbi.nlm.nih.gov/pubmed/30734676 http://dx.doi.org/10.2174/1566524019666190207143207 |
Ejemplares similares
-
Naoxintong attenuates Ischaemia/reperfusion Injury through inhibiting NLRP3 inflammasome activation
por: Wang, Yaqiong, et al.
Publicado: (2016) -
Naoxintong/PPARα Signaling Inhibits H9c2 Cell Apoptosis and Autophagy in Response to Oxidative Stress
por: Xu, Huimin, et al.
Publicado: (2016) -
Exosomes derived from M1 macrophages aggravate neointimal hyperplasia following carotid artery injuries in mice through miR-222/CDKN1B/CDKN1C pathway
por: Wang, Zeng, et al.
Publicado: (2019) -
Lanatoside C Promotes Foam Cell Formation and Atherosclerosis
por: Shi, Huairui, et al.
Publicado: (2016) -
NaoXinTong Inhibits the Development of Diabetic Retinopathy in db/db Mice
por: Liu, Mengyang, et al.
Publicado: (2015)